181 related articles for article (PubMed ID: 28318386)
1. Towards precision oncology in RET-aberrant cancers.
Subbiah V; Roszik J
Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
[No Abstract] [Full Text] [Related]
2. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract][Full Text] [Related]
3. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
4. Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC
Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
[TBL] [Abstract][Full Text] [Related]
5. Progress and potential impact of RET kinase targeting in cancer.
Mulligan LM
Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
[No Abstract] [Full Text] [Related]
6. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
7. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
9. Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.
Iams WT; Lovly CM
Cancer Discov; 2018 Jul; 8(7):797-799. PubMed ID: 29967074
[No Abstract] [Full Text] [Related]
10. Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.
Ding S; Wang R; Peng S; Luo X; Zhong L; Yang H; Ma Y; Chen S; Wang W
Biomed Pharmacother; 2020 Dec; 132():110901. PubMed ID: 33125973
[TBL] [Abstract][Full Text] [Related]
11. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
12. REToma: a cancer subtype with a shared driver oncogene.
Kohno T; Tabata J; Nakaoku T
Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
[TBL] [Abstract][Full Text] [Related]
13. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
14. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
15. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Carlomagno F; Guida T; Anaganti S; Provitera L; Kjaer S; McDonald NQ; Ryan AJ; Santoro M
Endocr Relat Cancer; 2009 Mar; 16(1):233-41. PubMed ID: 19029224
[TBL] [Abstract][Full Text] [Related]
16. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
17. 65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicine.
Mulligan LM
Endocr Relat Cancer; 2018 Aug; 25(8):T189-T200. PubMed ID: 29743166
[TBL] [Abstract][Full Text] [Related]
18. RET inhibitors go tumor-agnostic.
O'Leary K
Nat Med; 2022 Dec; 28(12):2449. PubMed ID: 36550308
[No Abstract] [Full Text] [Related]
19. Progresses Toward Precision Medicine in
Belli C; Anand S; Gainor JF; Penault-Llorca F; Subbiah V; Drilon A; Andrè F; Curigliano G
Clin Cancer Res; 2020 Dec; 26(23):6102-6111. PubMed ID: 32665298
[No Abstract] [Full Text] [Related]
20. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
